Protease inhibitors Doxorubicin

PROTEASE INHIBITORS DOXORUBICIN t risk of myelosuppression due to t plasma concentrations Due to 1 metabolism of doxorubicin by CYP3A4 isoenzymes owing to inhibition of those enzymes Monitor for t myelosuppression, peripheral neuropathy, myalgias and fatigue... [Pg.615]

Anticancer drugs etoposide, doxorubicin, vincristine Ca + channel blockers dUtiazem, verapamil HIV protease inhibitors indinavir, ritonavir Antibiotics/antifungals erythromycin, ketoconazole Hormones testosterone, progesterone Immunosuppressants cyclosporine, FK506 (tacrolimus)... [Pg.36]

Characteristics Nucleotide analogues Anticancer drugs 6-mercaptopurine Cyclic nucleotides cyclic AMP, cyclic GMP HIV protease inhibitors adefovir Anticancer drugs doxorubicin, etoposide ... [Pg.37]

A4 Barbiturates, carbamazepine, corticosteroids, efavirenz, phenytoin, rifampin, troglitazone Antiarrhythmics, antidepressants, azole antifungals, benzc iazepines, calcium channel blockers, cyclosporine, delavirdine, doxorubicin, efavirenz, erythromycin, estrogens, HIV protease inhibitors, nefazodone, paclitaxel, proton pump inhibitors, HMG-CoA reductase inhibitors, rifabutin, rifampin, sildenafil, SSRIs, tamoxifen, trazodone, vinca anticancer agents... [Pg.35]

Use of protease inhibitor-based regimens has been found to be associated with a higher incidence of infections and neutropenia in patients receiving cyciophosphamide, doxorubicin and etoposide (CDE) than use of a NNRTI-based regimen. [Pg.615]

Big Chemical Encyclopedia